Point of Care Lipid Test Market Size Worth USD 1,392.97 Million by 2034 | CAGR: 6.3%

The point of care (POC) lipid test market size is expected to reach USD 1,392.97 million by 2034, according to a new study by Polaris Market Research. The report “Point of Care Lipid Test Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Consumables), By Application, By Disease Indication, By End Use, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

A point of care (POC) lipid test is a diagnostic tool used to measure lipid levels such as total cholesterol, HDL, LDL, and triglycerides, directly at the site of patient care. It provides rapid results from a small blood sample, often within minutes, without needing a central laboratory.

Governments and health organizations are promoting routine cholesterol screening as part of national health programs aimed at reducing heart disease. Many public health campaigns emphasize early detection and regular lipid testing, especially for people with risk factors such as obesity, diabetes, or a family history of cardiovascular conditions. Some countries further provide funding or incentives for point of care testing in community clinics and pharmacies. These efforts are helping to normalize and increase the use of POC lipid tests across populations. Strong policy support and funding further accelerate the growth and accessibility of the market.

Bottom of Form

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/point-of-care-lipid-test-market/request-for-sample

There is a growing shift from reactive to preventive healthcare, where the goal is to catch diseases early or avoid them altogether. Lipid testing is a key tool in identifying risks for heart disease and related conditions before symptoms appear. Point of care testing devices make this process faster and easier, encouraging more frequent testing, especially in high-risk groups. These tests support better health outcomes by enabling early intervention and lifestyle changes. The demand for convenient lipid testing options is increasing significantly as awareness of preventive care rises among both patients and providers, thereby driving the POC lipid test market growth.

Point of Care Lipid Test Market Report Highlights

• In 2024, the consumables segment dominated with the largest share as these items are essential for every test and need to be replaced regularly, fueling consistent demand.
• The hypertriglyceridemia segment is expected to experience significant growth during the forecast period as hypertriglyceridemia is becoming increasingly common due to rising obesity rates.
• The market in North America dominated with the largest share in 2024, driven by rising cardiovascular disease prevalence, an aging population, and well-established healthcare infrastructure.
• The Asia Pacific market is projected to witness substantial growth during the forecast period, driven by increasing cardiovascular disease cases, growing health awareness, and expanding access to healthcare services.
• A few global key market players are Abbott Laboratories; Callegari Srl; F. Hoffmann-La Roche Ltd.; Menarini Group; MiCoBio; Nova Biomedical; SD Biosensor, Inc.; Sinocare Inc.; and VivaChek Biotech (Hangzhou) Co., Ltd.

Polaris Market Research has segmented the point of care lipid test market report on the basis of product, application, disease indication, end use, and region:

By Product (Revenue – USD Million, 2020–2034)

• Instruments
• Consumables

By Application (Revenue – USD Million, 2020–2034)

• Hyperlipidemia
• Hypertriglyceridemia
• Tangier Disease
• Hyperlipoproteinemia
• Familial Hypercholesterolemia
• Others

By Disease Indication (Revenue – USD Million, 2020–2034)

• Lipid and Lipoprotein Disorders
• Atherosclerosis
• Liver and Renal Diseases
• Diabetes Mellitus
• Others

By End Use (Revenue – USD Million, 2020–2034)

• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Others

By Regional Outlook (Revenue – USD Million, 2020–2034)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa